Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5 th, 2021. Novamind’s Strategic Investment is included in Bionomics’ latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the “Bionomics Financing”). With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). BNC210 has received Fast Track Designation from the U.S. In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210. TORONTO, ON / Febru/ Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. Nova Mentis (OTC: NMLSF) Receives Institutional Review Board Approval to Commence Psilocybin Clinical TrialĪI/ML Innovations (OTC: AIMLF) Introduces “Health Coach” – a Personalized AI-powered Health AdvisorĬedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment Nova Mentis (OTC: NMLSF) Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial Stria Lithium (OTC: SRCAF) reports best result to date from winter drilling at Pontax Property Nova Mentis (OTC: NMLSF) to Enter mRNA AI Diagnostics Business Stria Lithium (OTC: SRCAF) acquires additional mineral properties in lithium-rich region of Quebec close to its flagship Pontax Project to Develop an AI-powered Weight Loss Avatar and App “The $AMZN of Africa” Jumia Technologies (NYSE: JMIA) CEO Interview w Francis DufayĪI/ML Innovations (OTC: AIML) Announces Strategic Agreement with World Weight Loss, Inc. ![]() When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.Stria Lithium acquires strategic additional mineral properties in lithium-rich region of Quebec adjacent to its Pontax II ProjectĪI/ML Innovations (OTC: AIMLF) AI-driven, Patented Technology is Chosen for University of Alberta Respiratory Disease Clinical Study If you currently hold Novamind stock, you do not need to do anything. When the transaction is completed, Novamind shareholders will own around 18% of Numinus. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. ![]() Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |